Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus Q2´24: The CADENCE trial has started

By Antti SiltanenAnalyst
Mendus

Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with Ilixadencel.

00:00 Start
00:14 What has happened during Q2
04:58 The CADENCE trial
08:04 Main milestones in CADENCE
09:36 Immune activation in AML patients - What have you learned?
12:19 New trial with Ilixadencel
15:16 Timeline for the trial
15:54 Building readiness in AML

Stay up to date
Company management interviews

Recent videos

Arjo, Audiocast, Q4'25
30.01.2026 klo 14.00 Arjo
Midsona, Audiocast, Q4'25
30.01.2026 klo 12.00 Midsona
Elisa, Webcast, Q4'25
30.01.2026 klo 12.00 Elisa
Beijer Ref, Audiocast, Q4'25
30.01.2026 klo 11.00 Beijer Ref
Lifco, Audiocast, Q4'25
30.01.2026 klo 10.00 Lifco
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.